175 related articles for article (PubMed ID: 15221334)
1. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease.
Choei H; Sasaki N; Takeuchi M; Yoshida T; Ukai W; Yamagishi S; Kikuchi S; Saito T
Acta Neuropathol; 2004 Sep; 108(3):189-93. PubMed ID: 15221334
[TBL] [Abstract][Full Text] [Related]
2. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
3. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo.
Takeuchi M; Yamagishi S
Med Hypotheses; 2004; 63(3):453-5. PubMed ID: 15288367
[TBL] [Abstract][Full Text] [Related]
4. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease.
Dei R; Takeda A; Niwa H; Li M; Nakagomi Y; Watanabe M; Inagaki T; Washimi Y; Yasuda Y; Horie K; Miyata T; Sobue G
Acta Neuropathol; 2002 Aug; 104(2):113-22. PubMed ID: 12111353
[TBL] [Abstract][Full Text] [Related]
5. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M; Yamagishi S
Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
[TBL] [Abstract][Full Text] [Related]
6. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease.
Takeuchi M; Yamagishi S
J Alzheimers Dis; 2009; 16(4):845-58. PubMed ID: 19387117
[TBL] [Abstract][Full Text] [Related]
7. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.
Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG
Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease.
Takeuchi M; Sato T; Takino J; Kobayashi Y; Furuno S; Kikuchi S; Yamagishi S
Med Hypotheses; 2007; 69(6):1358-66. PubMed ID: 17888585
[TBL] [Abstract][Full Text] [Related]
9. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains.
Lüth HJ; Ogunlade V; Kuhla B; Kientsch-Engel R; Stahl P; Webster J; Arendt T; Münch G
Cereb Cortex; 2005 Feb; 15(2):211-20. PubMed ID: 15238435
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress in Alzheimer's disease hippocampus: a topographical study.
Cruz-Sánchez FF; Gironès X; Ortega A; Alameda F; Lafuente JV
J Neurol Sci; 2010 Dec; 299(1-2):163-7. PubMed ID: 20863531
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species.
Niiya Y; Abumiya T; Shichinohe H; Kuroda S; Kikuchi S; Ieko M; Yamagishi S; Takeuchi M; Sato T; Iwasaki Y
Brain Res; 2006 Sep; 1108(1):179-87. PubMed ID: 16872585
[TBL] [Abstract][Full Text] [Related]
12. alpha-Internexin immunoreactivity reflects variable neuronal vulnerability in Alzheimer's disease and supports the role of the beta-amyloid plaques in inducing neuronal injury.
Dickson TC; Chuckowree JA; Chuah MI; West AK; Vickers JC
Neurobiol Dis; 2005 Mar; 18(2):286-95. PubMed ID: 15686957
[TBL] [Abstract][Full Text] [Related]
13. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF
Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749
[TBL] [Abstract][Full Text] [Related]
14. The Alzheimer disease-related calcium-binding protein Calmyrin is present in human forebrain with an altered distribution in Alzheimer's as compared to normal ageing brains.
Bernstein HG; Blazejczyk M; Rudka T; Gundelfinger ED; Dobrowolny H; Bogerts B; Kreutz MR; Kuznicki J; Wojda U
Neuropathol Appl Neurobiol; 2005 Jun; 31(3):314-24. PubMed ID: 15885068
[TBL] [Abstract][Full Text] [Related]
15. Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains.
Kuhla B; Boeck K; Schmidt A; Ogunlade V; Arendt T; Münch G; Lüth HJ
Neurobiol Aging; 2007 Jan; 28(1):29-41. PubMed ID: 16427160
[TBL] [Abstract][Full Text] [Related]
16. Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia.
Takeda M; Ohnuma T; Takeuchi M; Katsuta N; Maeshima H; Takebayashi Y; Higa M; Nakamura T; Nishimon S; Sannohe T; Hotta Y; Hanzawa R; Higashiyama R; Shibata N; Gohda T; Suzuki Y; Yamagishi S; Tomino Y; Arai H
Neurosci Lett; 2015 Apr; 593():51-5. PubMed ID: 25766756
[TBL] [Abstract][Full Text] [Related]
17. Immunochemical crossreactivity of antibodies specific for "advanced glycation endproducts" with "advanced lipoxidation endproducts".
Richter T; Münch G; Lüth HJ; Arendt T; Kientsch-Engel R; Stahl P; Fengler D; Kuhla B
Neurobiol Aging; 2005 Apr; 26(4):465-74. PubMed ID: 15653175
[TBL] [Abstract][Full Text] [Related]
18. Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology.
Kar S; Poirier J; Guevara J; Dea D; Hawkes C; Robitaille Y; Quirion R
Neurobiol Aging; 2006 Feb; 27(2):199-210. PubMed ID: 16399207
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus.
Guillemin GJ; Brew BJ; Noonan CE; Takikawa O; Cullen KM
Neuropathol Appl Neurobiol; 2005 Aug; 31(4):395-404. PubMed ID: 16008823
[TBL] [Abstract][Full Text] [Related]
20. TAGE (toxic AGEs) hypothesis in various chronic diseases.
Takeuchi M; Yamagishi S
Med Hypotheses; 2004; 63(3):449-52. PubMed ID: 15288366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
